Inhaled Corticosteroid Device Market By Product Type (Pressurized Metered-Dose Inhalers, Dry Powder Inhalers, Breath-Actuated Inhalers, Nebulizers); By Application (Asthma, Chronic Obstructive Pulmonary Disease, Severe and Eosinophilic Asthma, Other Chronic Respiratory Conditions); By End User (Hospitals and Clinics, Specialty Respiratory Centers, Home Healthcare Settings, Ambulatory Care Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Inhaled Corticosteroid Device Market: Device Usability, Combination Platforms, and Low-Carbon Redesign Reshape Respiratory Care

The Global Inhaled Corticosteroid Device Market was valued at USD 13.58 billion in 2025 and is projected to reach USD 21.66 billion by 2032, growing at a CAGR of 6.9%, according to Strategic Market Research.

 

The inhaled corticosteroid device market covers integrated drug-device products that deliver corticosteroids through pressurized metered-dose inhalers, dry powder inhalers, and nebulized formulations. The commercial market includes standalone corticosteroids, inhaled corticosteroid and long-acting bronchodilator combinations, anti-inflammatory reliever products, and triple-therapy inhalers containing corticosteroid, LABA, and LAMA components.

 

Established corticosteroid molecules include fluticasone, budesonide, beclomethasone, mometasone, and ciclesonide. However, market value is increasingly concentrated in combination devices rather than older single-drug controllers. Fixed combinations reduce the number of prescriptions and devices required, while giving manufacturers opportunities to differentiate through dosing frequency, device design, formulation, and approved indications.

 

Large Asthma and COPD Populations Sustain Recurring Device Demand

Asthma represents the broadest addressable population for corticosteroid-containing inhalers. The World Health Organization estimates that 363 million people were living with asthma in 2023, while the disease caused approximately 442,000 deaths during the year. In the United States, 27.8 million people had current asthma in 2023, including approximately 23 million adults and 4.8 million children. 

COPD expands the potential device population, although corticosteroid-containing devices are generally directed toward selected patients rather than every person diagnosed with COPD. Nearly 16 million U.S. adults have COPD, while many additional cases remain undiagnosed. Ageing populations and continued exposure to smoking, workplace pollutants, household smoke, and urban air pollution support long-term demand for maintenance inhalers. 

The patient pool does not convert automatically into device sales. Diagnosis rates, prescription coverage, inhaler availability, affordability, refill persistence, and the ability to use a particular device determine the commercially treated population. The WHO reports that steroid inhalers remain unavailable across many public primary-care systems in low- and lower-middle-income countries, leaving a substantial gap between medical need and regular device access.

This access gap creates two different commercial markets. High-income countries support premium combination devices, once-daily formats, connected inhalers, and environmentally reformulated products. Lower-income markets depend more heavily on affordable devices, public-sector procurement, generic formulations, local manufacturing, and consistent pharmacy distribution.

 

Pressurized Metered-Dose Inhalers Retain a Large Installed Base

Pressurized metered-dose inhalers, or pMDIs, remain one of the most widely recognized delivery formats. They use a pressurized canister and metering valve to release a defined aerosol dose. Their compact size, established manufacturing base, and suitability for patients with limited inspiratory strength support continued demand across adult and pediatric care.

The device format also presents commercial challenges. Patients must coordinate actuation with inhalation unless the product is breath-actuated or used with a spacer. Incorrect timing can reduce the amount of medicine reaching the lungs, increasing the importance of patient instruction and device familiarity.

For manufacturers, pMDIs require specialized aerosol formulations, canisters, metering valves, actuators, elastomer components, and high-precision filling lines. The interaction between these components can affect spray pattern, particle size, dose delivery, leakage, and shelf stability. These requirements create higher technical and regulatory barriers than those associated with conventional oral medicines.

The installed base of pMDI production equipment and patient familiarity will prevent an immediate shift away from this format. The larger transition will involve replacing older propellants with alternatives that have a lower environmental impact.

 

Dry Powder Inhalers Compete Through Portability and Propellant-Free Delivery

Dry powder inhalers, or DPIs, deliver medication using the patient’s own inhalation effort rather than a pressurized propellant. This removes the need to coordinate manual actuation with breathing and avoids the greenhouse-gas emissions associated with pMDI propellants.

DPI platforms include single-dose capsule devices, blister-based systems, reservoir devices, and pre-metered multidose inhalers. These differences influence manufacturing cost, moisture protection, refill design, dosing steps, and patient convenience. Multidose formats are generally positioned for routine maintenance treatment because they reduce the need to load an individual capsule before each use.

The performance of a DPI depends partly on the user generating sufficient inspiratory airflow. This can limit suitability for very young children, frail older adults, patients experiencing a severe exacerbation, and people with advanced respiratory impairment. Device selection therefore cannot be based only on environmental impact or acquisition price.

Manufacturers that maintain a familiar DPI platform across standalone, dual-combination, and triple-combination products can retain patients as treatment intensity changes. Platform continuity also reduces retraining requirements for physicians, pharmacists, and patients.

 

Breath-Actuated Devices Address Coordination Problems

Breath-actuated inhalers are designed to release the dose when the user inhales through the device. Their commercial value comes from reducing the hand-breath coordination problems associated with conventional pMDIs while maintaining a compact handheld format.

These devices can appeal to children, older adults, and patients who repeatedly demonstrate poor conventional inhaler technique. However, breath-actuated systems require additional mechanical components and must be engineered to trigger within an appropriate inhalation range. This increases device-development complexity and may raise manufacturing costs compared with simpler inhalers.

Their adoption depends on whether insurers and healthcare providers consider the improvement in usability sufficient to justify any price difference. Device companies must demonstrate that the design produces practical improvements in correct use, persistence, or clinical outcomes rather than relying on convenience claims alone.

 

Nebulizers Retain a Focused Role in Pediatric and High-Dependency Care

Nebulizers convert liquid formulations into a mist inhaled through a mouthpiece or mask. They do not require the same actuation coordination or forceful inhalation as handheld devices, making them useful for young children, older patients, people with physical or cognitive limitations, and patients receiving treatment in hospitals or home-care settings.

Their role in routine ambulatory treatment is more limited because administration takes longer, the equipment is less portable, and cleaning requirements are greater. The nebulized corticosteroid device segment therefore competes less on everyday convenience and more on its ability to serve patients who cannot reliably use handheld inhalers.

Portable mesh nebulizers are improving mobility and treatment time, but higher acquisition costs can restrict adoption. Hospital purchasing, home respiratory-care providers, pediatric prescribing, and insurance coverage remain important demand channels for this segment.

 

Device Technique Directly Affects Prescription Value

Incorrect inhaler use remains one of the largest barriers to obtaining the expected value from a corticosteroid-containing device. The Global Initiative for Asthma continues to emphasize ICS-containing treatment while recognizing that inhaler selection and correct use are central to treatment performance. 

Common device-related errors include failing to exhale before inhalation, insufficient inspiratory effort, poor coordination, incorrect device preparation, failing to hold the breath after inhalation, and not recognizing when the device is empty. These problems can result in therapy escalation even when the original product might have worked if used correctly.

Ease of use therefore has direct commercial implications. Devices with fewer preparation steps, visible dose counters, clear feedback, ergonomic mouthpieces, and consistent operation can improve patient confidence and reduce switching resistance.

Payer-mandated substitution can create an additional problem when patients are moved from a familiar branded device to a generic inhaler with different operating steps. Although the active formulation may be equivalent, the patient may require retraining. Manufacturers that closely reproduce the handling characteristics of the reference device can reduce this barrier.

 

Combination Inhalers Are Increasing the Value of Each Device

Market revenue is moving from basic standalone corticosteroid inhalers toward devices that deliver two or three therapeutic components. The device becomes more valuable because it replaces multiple prescriptions and concentrates treatment into one platform.

In asthma, corticosteroid-containing reliever strategies are increasing the role of devices that can be used for both maintenance and symptom-driven treatment. Current asthma guidelines recommend ICS-containing therapy for adults, adolescents, and most children, expanding the commercial importance of devices that can support different stages of treatment.

In COPD, single-inhaler triple therapy has created a premium device category for patients who remain uncontrolled on simpler regimens. These devices require the stable co-delivery of multiple active components while maintaining dose uniformity throughout the product’s shelf life.

GSK’s Trelegy Ellipta generated approximately £2.99 billion in 2025 sales, increasing 11% at reported exchange rates and 13% at constant exchange rates. Although the revenue is reported for the complete medicine, the performance also demonstrates the commercial strength of a recognized multidose platform supporting once-daily triple therapy.

Device manufacturers benefit when one platform supports several strengths, indications, or combinations. Shared platform architecture can reduce some development and manufacturing duplication while strengthening recognition among prescribers and patients.

 

Low-Carbon Propellants Are Creating a Major Device-Replacement Cycle

Environmental policy is becoming one of the strongest device-specific market forces. Conventional pMDIs use hydrofluorocarbon propellants that contribute to greenhouse-gas emissions. Regulators and healthcare systems are encouraging lower-emission devices while recognizing that pMDIs remain necessary for many patients.

The European Medicines Agency has issued guidance describing the quality, non-clinical, and clinical data required when manufacturers replace existing pMDI propellants with lower-global-warming-potential alternatives. A propellant change can alter aerosol behaviour, delivered dose, lung exposure, and device-component compatibility, meaning manufacturers cannot treat the transition as a simple packaging change.

In May 2025, UK regulators approved a reformulated version of AstraZeneca’s Trixeo Aerosphere using a propellant with 99.9% lower global-warming potential than the propellant used in the existing version. The approval maintained the established pMDI format while reducing its environmental footprint. 

This transition creates revenue opportunities for propellant suppliers, valve manufacturers, canister producers, contract development companies, analytical laboratories, and aerosol-filling specialists. It also increases capital requirements because manufacturers may need to modify filling equipment, validate new components, conduct stability testing, and obtain regulatory approval for each reformulated product.

Large respiratory companies with established aerosol-development capabilities may move faster than smaller generic manufacturers. However, generic suppliers that complete the transition efficiently could gain contracts from healthcare systems seeking both lower prices and lower-carbon products.

 

Complex Generic Development Limits Price-Based Competition

Generic competition has reduced revenue generated by several mature corticosteroid inhalers, but inhaled products are more difficult to reproduce than conventional tablets. Product performance depends on complex interactions among the device, formulation, and patient, making equivalent-product development more expensive and time-consuming.

A generic developer must evaluate emitted dose, aerodynamic particle size, airflow resistance, spray characteristics, device operation, and patient interaction. A product containing the same active ingredient may still fail to provide an equivalent user experience or delivery profile if the device differs materially.

The FDA approved Wixela Inhub in January 2019 as the first generic version of Advair Diskus. The approval demonstrated that complex dry powder combination inhalers could face direct generic competition, but it also illustrated the development and regulatory requirements associated with creating an equivalent delivery system. 

Generic entry increases payer leverage and can redirect prescriptions away from established brands. Originator companies are responding by developing combination platforms, broader indications, once-daily devices, breath-actuated systems, connected features, and environmentally reformulated inhalers.

 

Connected Features Are Moving From Novelty to Adherence Support

Digital inhalers and connected add-on sensors can record device opening, actuation, inhalation events, and usage patterns. Their main commercial purpose is to identify poor adherence, excessive reliever use, and incorrect technique before the patient experiences serious deterioration.

Connected devices may support remote monitoring programs, clinical studies, value-based care contracts, and specialist management of difficult-to-control asthma. The commercial model is more complex than selling a conventional inhaler because the manufacturer must account for sensor cost, software maintenance, data security, integration with clinical systems, and reimbursement.

Digital features are unlikely to be included in every low-cost inhaler. Adoption will be stronger in severe asthma, pediatric management, clinical research, and health systems willing to pay for adherence information. Simpler mechanical feedback and dose-counting functions will remain more practical in price-sensitive markets.

 

Manufacturing Scale and Component Control Determine Supplier Strength

Inhaled corticosteroid devices require precise coordination among formulation manufacturing, device assembly, filling, testing, and packaging. Critical inputs include valves, canisters, actuators, blister foils, polymer housings, dose counters, seals, desiccants, and propellants.

Supply interruptions affecting even one specialized component can delay finished-product manufacturing. Respiratory companies therefore benefit from multiple qualified suppliers, long-term component contracts, and control over critical filling capacity.

Platform standardization can improve manufacturing economics. A company using a common device architecture across several products can spread tooling, testing, training, and production investments over a larger volume. However, a quality problem affecting a shared platform can also disrupt multiple products at once.

Contract development and manufacturing organizations can gain business from companies that lack their own aerosol or DPI capabilities. Low-carbon reformulation is likely to increase outsourcing demand because companies need specialized analytical, filling, and regulatory expertise.

 

Key Players Compete Through Distinct Inhaler Device Platforms

Leading companies in the inhaled corticosteroid device market compete through proprietary delivery platforms rather than through corticosteroid formulations alone. Each device family differs in dose preparation, inhalation effort, actuation method, dosing frequency, environmental profile, and suitability for combination products.

 

GSK: Ellipta and Diskus Dry Powder Inhalers

GSK markets two of the most established multidose dry powder inhaler platforms.

Ellipta is a once-daily multidose dry powder inhaler used for products such as Arnuity Ellipta and the triple-combination device Trelegy Ellipta. The platform uses preloaded blister strips and includes a dose counter. Its use across several treatment levels allows the company to retain a familiar device format as patient requirements change.

Diskus is a multidose dry powder device used for Advair Diskus and other fluticasone-containing products. Its long market presence has created strong physician and patient familiarity, although it now faces competition from generic alternatives.

The use of common device families across standalone, dual, and triple therapies enables GSK to build platform recognition rather than marketing each respiratory product through a completely different operating system.

 

AstraZeneca: Turbuhaler and Aerosphere Platforms

AstraZeneca operates both dry powder and pressurized delivery platforms.

Turbuhaler is a multidose dry powder inhaler associated with products such as Symbicort Turbuhaler and Pulmicort Turbuhaler in several international markets. It is breath-operated and does not require a propellant.

Aerosphere is a pressurized metered-dose inhaler platform used for combination respiratory products such as Breztri Aerosphere and Trixeo Aerosphere. AstraZeneca is adapting the platform to next-generation propellants with substantially lower global-warming potential.

This dual-platform strategy enables AstraZeneca to serve patients who prefer or require either dry powder or pressurized aerosol delivery.

 

Teva Pharmaceutical Industries: RediHaler and Digihaler Platforms

Teva has focused on breath-actuated and digitally supported inhaler formats.

QVAR RediHaler is a breath-actuated metered-dose inhaler containing beclomethasone. The device automatically releases the dose during inhalation, reducing the coordination difficulties associated with conventional manually actuated pMDIs.

Digihaler is a dry powder inhaler platform with built-in electronic sensors capable of recording inhalation events and device-use information. Its digital functions are intended to support adherence monitoring and identify incorrect or inconsistent use.

Teva’s device portfolio is positioned around easier actuation and connected respiratory-care capabilities rather than conventional inhaler design alone.

 

Viatris: Wixela Inhub Dry Powder Inhaler

Viatris competes through the Wixela Inhub, a multidose dry powder inhaler developed as a generic alternative to Advair Diskus. The device delivers a fluticasone and salmeterol combination and is available in multiple strengths.

Wixela Inhub demonstrates how generic manufacturers must reproduce not only the formulation but also airflow resistance, dose delivery, and patient-facing operation. Its commercial relevance comes from offering a lower-cost alternative in a category historically dominated by branded dry powder devices.

 

Chiesi Farmaceutici: Pressurized Metered-Dose Inhalers

Chiesi has a strong position in pressurized metered-dose inhalers, particularly in European respiratory care. Its portfolio includes corticosteroid-containing combination inhalers delivered through compact pMDI platforms.

The company is investing in lower-carbon propellant technology to retain the clinical benefits of pressurized delivery while reducing environmental emissions. This strategy is especially relevant for patients who cannot generate sufficient inspiratory flow for dry powder inhalers.

 

Cipla: Affordable Metered-Dose, Dry Powder, and Nebulized Devices

Cipla manufactures a broad portfolio of generic respiratory devices, including:

• Pressurized metered-dose inhalers

• Dry powder inhalers

• Capsule-based inhaler devices

• Nebulized corticosteroid formulations

The company’s competitive strength comes from affordable manufacturing and distribution across India, Africa, Latin America, and other price-sensitive markets. Cipla’s device range supports public procurement and pharmacy access where premium branded platforms may remain unaffordable.

 

Boehringer Ingelheim: Respimat Soft Mist Platform

Boehringer Ingelheim developed the Respimat Soft Mist Inhaler, which releases a slow-moving aerosol cloud without using the conventional high-velocity spray associated with standard pMDIs. The platform is mainly used for bronchodilator products rather than standalone inhaled corticosteroids.

Respimat remains relevant to the wider respiratory-device market because its soft-mist format provides an alternative delivery approach for patients who have difficulty coordinating conventional inhalers. However, Boehringer Ingelheim has a more limited direct position in corticosteroid-containing devices than GSK, AstraZeneca, Teva, Viatris, Chiesi, and Cipla.

 

Device Platforms of Major Market Participants

• GSK: Ellipta DPI and Diskus DPI

• AstraZeneca: Turbuhaler DPI and Aerosphere pMDI

• Teva: RediHaler breath-actuated MDI and Digihaler connected DPI

• Viatris: Wixela Inhub DPI

• Chiesi: Conventional and lower-carbon pMDIs

• Cipla: Generic pMDIs, DPIs, capsule inhalers, and nebulized devices

• Boehringer Ingelheim: Respimat soft-mist inhaler, mainly used for non-ICS respiratory products

These portfolios show that competition is divided among dry powder systems, pressurized aerosol inhalers, breath-actuated devices, connected inhalers, soft-mist platforms, and nebulization systems. Companies with multiple delivery formats can address a wider range of patient abilities, price points, and regional prescribing preferences.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 13.58 Billion
Revenue Forecast in 2032	USD 21.66 Billion
Overall Growth Rate	CAGR of 6.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Pressurized Metered-Dose Inhalers, Dry Powder Inhalers, Breath-Actuated Inhalers, Nebulizers
By Application	Asthma, Chronic Obstructive Pulmonary Disease, Severe and Eosinophilic Asthma, Other Chronic Respiratory Conditions
By End User	Hospitals and Clinics, Specialty Respiratory Centers, Home Healthcare Settings, Ambulatory Care Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising asthma and COPD burden, growing preference for portable respiratory drug-delivery devices, increasing adoption of home-based inhalation therapy, product innovation in breath-actuated and dry powder inhalers
Customization Option	Available upon request